Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth quarter, but that compared unfavorably with ...

India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.

Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas.